Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.
Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.
And this, ladies and gentlemen, is why you don’t give your data to companies: their executives and shareholders care more about their bottom line than your privacy.
Exactly, and you cannot hope to see any meaningful regulation out of the current government.
The company will just buy The Secret Service/Trump’s Presidential Library a fleet of Rolls Royce and he’ll intimidate congress into silence.